Evoke Pharma Inc (EVOK) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Customers, else..
 
Evoke Pharma Inc   (NASDAQ: EVOK)
 

Evoke Pharma Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EVOK Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) 61.4 % 10.17 % 8.71 % 7.86 %
Q / Q Revenue Growth (Q3 MRQ) 14.17 % 5.71 % 4.49 % 4.58 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 67.4 % 7.46 % 5.81 % %
Sequential Revenue Growth (for 12 months ending Q3 TTM) 12.74 % 1.55 % 1.72 % 1.97 %
Revenue 5 Year Average Growth - 14.14 % 10.99 % 7.73 %


EVOK's Growth Comparisons in III. Quarter 2025




Strong but slowing Revenue rise by Evoke Pharma Inc of 61.4% year on year , in the third quarter 2025 to 4 millions, was higher than the 10.17% rise in the Major Pharmaceutical Preparations industry, and 8.71% growth in the Healthcare sector. Above the average sales gains in the Healthcare and in the Major Pharmaceutical Preparations industry, helped to elevate overall market growth to 7.86%.

Top-line improved by 14.17% from the second quarter. Looking into annual sales rise of %, and S & P 500's average yearly sales growth is 7.73% over the five years, including only Businesses with the third quarter 2025 Results. Evoke Pharma Inc grew less than the market.

EVOK Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Pharmaceutical Products
61.4 %
14.17 %
Total
61.4 %
14.17 %


Growth Rates of EVOK's Income in the third quarter 2025


EVOK Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) - 34.38 % 26.24 % 14.52 %
Sequential Operating Income Change (Q3 MRQ) - 12.78 % 10.95 % 7.3 %
Y / Y Operating Income Growth (Q3 TTM) - 95.25 % 50.46 % 6.44 %
Sequential Operating Income Growth (Q3 TTM) - 14.09 % 9.41 % 3.54 %
Operating Income 5 Year Avg. Change - 0.11 % -0.96 % 9 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) - 52.06 % 22.16 % 18.96 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) - 14.63 % 15.11 % 3.03 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) - - 40.03 % 14.26 %
Sequential Income from Cont. Ops. Change (Q3 TTM) - - 14.88 % 4.45 %
Income from Cont. Ops. 5 Year Avg. Change - -18.69 % -17.93 % 8.34 %

EVOK Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) - 55.22 % 13.73 % 18.25 %
Q / Q Net Income Growth (Q3 MRQ) - 15.16 % 13.53 % 3.11 %
Y / Y Net Income Change (Q3 TTM) - 175.38 % 90.39 % 15.08 %
Sequential Net Income Change (Q3 TTM) - 18.47 % 9.36 % 4.28 %
Net Income 5 Year Avg. Growth - 14.51 % 6.2 % 9.47 %

EVOK's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) - 24.29 % 22.16 % 18.96 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) - -5.39 % 15.11 % 3.03 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) - - - -47.94 %
EPS from Cont. Ops. 5 Year Avg. Growth - -29.47 % -17.93 % 8.34 %



EVOK EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) - 26.88 % 13.73 % 8.34 %
Q / Q EPS Net Growth (Q3 MRQ) - -4.95 % 13.53 % 3.11 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - -66.9 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) - - - -47.94 %
EPS Net 5 Year Avg. Change - 14.51 % 6.2 % 9.47 %



Evoke Pharma Inc reported bottom-line of $ -0.45 in the third quarter, compare to $ -0.94 in the same quarter a year ago. Major Pharmaceutical Preparations industry grew by 26.88%, while Healthcare sector increased by 13.73%, and overall market improved by 18.25%.

The bottom-line improved by 14.17% from the second quarter. Looking into annual income per share rise of %, and S & P 500's average yearly income per share growth is 9.47% over the five years, including only Businesses with the third quarter 2025 earnings reports. Evoke Pharma Inc grew less than the market.

EVOK Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) - 12.04 % 24.3 % 73.68 %
Sequential Free Cash Flow Change (Q3 MRQ) - 161.13 % 155.33 % 27.4 %
Y / Y Free Cash Flow Change (Q3 TTM) - 33.5 % 32.18 % 19.32 %
Sequential Free Cash Flow Change (Q3 TTM) - 10.62 % 12.15 % 12.94 %
Free Cash Flow 5 Year Avg. Change - 9.45 % 6.34 % 10.76 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - - - -
Sequential Net Cash Flow Change (Q3 MRQ) - - - -
Y / Y Net Cash Flow Change (Q3 TTM) -95.59 % -12.79 % 149.69 % -
Sequential Net Cash Flow Change (Q3 TTM) - 61.16 % 458.93 % -
Net Cash Flow 5 Year Avg. Change 91.4 % -8.21 % -1.7 % -32.35 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) - 24.12 % 13.38 % 22.12 %
Sequential Capital Expenditures Change (Q3 MRQ) - 18.9 % 11.28 % 8.66 %
Y / Y Capital Expenditures Change (Q3 TTM) - 12.75 % 6.11 % 22.98 %
Sequential Capital Expenditures Change (Q3 TTM) - 4.74 % 2.51 % 5.32 %
Capital Expenditures 5 Year Avg. Change - 10.81 % 9 % 10.74 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.